MENU
Showcases Stock ranks Forex

Kazia Therapeutics Ltd ADR (KZIA)
0.3137  -0.006 (-1.78%) 03-27 16:00
Open: 0.299 Pre. Close: 0.3194
High: 0.32 Low: 0.293
Volume: 290,045 Market Cap: 6(M)
Stock Technical Analysis
Overall:     
Target: Six months: 0.39
One year: 0.45
Support: Support1: 0.24
Support2: 0.19
Resistance: Resistance1: 0.33
Resistance2: 0.39
Pivot: 0.25
Moving Averages: MA(5): 0.28
MA(20): 0.24
MA(100): 0.40
MA(250): 0.79
MACD: MACD(12,26):
Signal(12,26,9): -0.01
%K %D: %K(14,3): 89.92
%D(3): 82.46
RSI: RSI(14): 61.38
52-Week: High: 1.68
Low: 0.19
Change(%): -69.8
Average Vol(K): 3-Month: 843
10-Days: 655
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 0.321 - 0.322 0.322 - 0.324
Low: 0.286 - 0.288 0.288 - 0.29
Close: 0.307 - 0.31 0.31 - 0.313
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ KZIA ] has closed below upper band by 2.3%. Bollinger Bands are 33.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Stock chart
Stock News
Wed, 27 Mar 2024
XLO Stock Quote Price and Forecast - CNN

Tue, 26 Mar 2024
NERV Stock Quote Price and Forecast - CNN

Fri, 22 Mar 2024
This trade activity should not be overlooked: Kazia Therapeutics Limited ADR (KZIA) - SETE News

Mon, 26 Apr 2021
Proactive news headlines including Chase Mining Corporation, Red River Resources, Aurumin and Kazia Therapeutics - The Globe and Mail

Tue, 20 Apr 2021
Proactive news headlines including Queensland Pacific Metals, Moho Resources, Kazia Therapeutics and Perseus ... - The Globe and Mail

Tue, 30 Mar 2021
Proactive news headlines including Oklo Resources, Strategic Elements, AVZ Minerals and Kazia Therapeutics - The Globe and Mail

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) -14.63
Shares Float (M)
% Held by Insiders 26360000.00
% Held by Institutions 1960000000.00
Shares Short (K)
Shares Short Prior Month (K)
Stock Financials
EPS
Book Value (p.s.) -0.740
Profit Margin
Operating Margin
Return on Assets (ttm) 890.0
Return on Equity (ttm) 295.3
Qtrly Rev. Growth -135.0
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.978
Qtrly Earnings Growth -22280000.00
Operating Cash Flow (M)
Levered Free Cash Flow (M)
Stock Valuation
PE Ratio
PEG Ratio
Price to Book value -0.42
Price to Sales
Price to Cash Flow
Stock Dividends
Dividend 45930.000
Dividend Yield 146413.78
Dividend Growth 181720.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android